ticlopidine has been researched along with Kidney Diseases in 29 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 7.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| "Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge." | 7.80 | Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. ( Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC, 2014) |
| " We report a case of a large renal hematoma following SWL that resulted in nephrectomy in a type 2 diabetic patient with primary hyperparathyroidism using clopidogrel due to coronary heart disease CHD." | 7.73 | Serious clopidogrel associated renal hematoma in a type 2 diabetic patient with primary hyperparathyroidism after extracorporeal shock wave lithotripsy. ( Agil, C; Akay, F; Akay, H; Bahceci, M; Tuzcu, A, 2005) |
| "Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial." | 5.38 | Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? ( DiNicolantonio, JJ; Serebruany, VL, 2012) |
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 3.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| "Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge." | 3.80 | Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. ( Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC, 2014) |
| " We report a case of a large renal hematoma following SWL that resulted in nephrectomy in a type 2 diabetic patient with primary hyperparathyroidism using clopidogrel due to coronary heart disease CHD." | 3.73 | Serious clopidogrel associated renal hematoma in a type 2 diabetic patient with primary hyperparathyroidism after extracorporeal shock wave lithotripsy. ( Agil, C; Akay, F; Akay, H; Bahceci, M; Tuzcu, A, 2005) |
| " A low postoperative dose of aprotinin in patients receiving clopidogrel is safe and has comparable effects regarding postoperative bleeding complications as a high dose." | 2.75 | Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. ( Istad, R; Ringdal, MA; Tangen, G; Tølløfsrud, S; Øvrum, E; Øystese, R, 2010) |
| "Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial." | 1.38 | Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? ( DiNicolantonio, JJ; Serebruany, VL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 15 (51.72) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qadir, MI | 1 |
| Rehman, A | 1 |
| HamidAkash, MS | 1 |
| Irfan, M | 1 |
| Baber, M | 1 |
| Hussain, SB | 1 |
| Baber, U | 1 |
| Bander, J | 1 |
| Karajgikar, R | 1 |
| Yadav, K | 1 |
| Hadi, A | 1 |
| Theodoropolous, K | 1 |
| Gukathasan, N | 1 |
| Roy, S | 1 |
| Sayeneni, S | 1 |
| Scott, SA | 1 |
| Kovacic, JC | 1 |
| Yu, J | 1 |
| Sartori, S | 1 |
| Mehran, R | 1 |
| Uribarri, J | 1 |
| Badimon, JJ | 1 |
| Muntner, P | 1 |
| Moreno, P | 1 |
| Kini, AS | 1 |
| Sharma, SK | 1 |
| Cuschieri, JR | 1 |
| Drawz, P | 1 |
| Falck-Ytter, Y | 1 |
| Wong, RC | 1 |
| Ozyalvacli, ME | 1 |
| Uyeturk, U | 1 |
| Halicioglu, S | 1 |
| Kargı, E | 1 |
| Guo, LZ | 1 |
| Kim, MH | 1 |
| Kim, TH | 1 |
| Park, JS | 1 |
| Jin, E | 1 |
| Shim, CH | 1 |
| Choi, SY | 1 |
| Serebruany, VL | 2 |
| Eusebi, LH | 1 |
| Rabitti, S | 1 |
| Artesiani, ML | 1 |
| Gelli, D | 1 |
| Montagnani, M | 1 |
| Zagari, RM | 1 |
| Bazzoli, F | 1 |
| Sakariassen, KS | 1 |
| Alberts, P | 1 |
| Fontana, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 1 |
| Sorensen, AS | 1 |
| Øvrum, E | 1 |
| Tangen, G | 1 |
| Tølløfsrud, S | 1 |
| Ringdal, MA | 1 |
| Øystese, R | 1 |
| Istad, R | 1 |
| James, S | 1 |
| Budaj, A | 1 |
| Aylward, P | 1 |
| Buck, KK | 1 |
| Cannon, CP | 1 |
| Cornel, JH | 1 |
| Harrington, RA | 1 |
| Horrow, J | 1 |
| Katus, H | 1 |
| Keltai, M | 1 |
| Lewis, BS | 1 |
| Parikh, K | 1 |
| Storey, RF | 1 |
| Szummer, K | 1 |
| Wojdyla, D | 1 |
| Wallentin, L | 1 |
| Park, KW | 1 |
| Park, JJ | 1 |
| Jeon, KH | 1 |
| Kang, SH | 1 |
| Oh, IY | 1 |
| Yang, HM | 1 |
| Cho, HJ | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Hayashi, K | 1 |
| Ohtsu, F | 1 |
| Yano, R | 1 |
| Sakakibara, J | 1 |
| Goto, N | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Müller, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| May, AE | 1 |
| Flather, M | 1 |
| Gawaz, M | 1 |
| Geisler, T | 1 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Woo, JS | 1 |
| Kim, W | 1 |
| Lee, SR | 1 |
| Jung, KH | 1 |
| Kim, WS | 1 |
| Lew, JH | 1 |
| Lee, TW | 1 |
| Lim, CK | 1 |
| Choi, YH | 1 |
| Suh, SH | 1 |
| Choi, JS | 1 |
| Kim, CS | 1 |
| Sim, DS | 1 |
| Bae, EH | 1 |
| Lim, SY | 1 |
| Ma, SK | 1 |
| Jeong, MH | 1 |
| Kim, SW | 1 |
| DiNicolantonio, JJ | 1 |
| Fernandez, JS | 1 |
| Sadaniantz, BT | 1 |
| Sadaniantz, A | 1 |
| Bahceci, M | 1 |
| Tuzcu, A | 1 |
| Akay, F | 1 |
| Agil, C | 1 |
| Akay, H | 1 |
| Ohtake, T | 1 |
| Kobayashi, S | 1 |
| Okamoto, K | 1 |
| Oka, M | 1 |
| Maesato, K | 1 |
| Yasu, T | 1 |
| Moriya, H | 1 |
| Otrock, ZK | 1 |
| Sawaya, JI | 1 |
| Zebian, RC | 1 |
| Taher, AT | 1 |
| de Silva, R | 1 |
| Nikitin, NP | 1 |
| Witte, KK | 1 |
| Rigby, AS | 1 |
| Loh, H | 1 |
| Nicholson, A | 1 |
| Bhandari, S | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Dorval, JF | 1 |
| Soulez, G | 1 |
| Berry, C | 1 |
| Bonan, R | 1 |
| Tu, X | 1 |
| Chen, X | 1 |
| Xie, Y | 1 |
| Shi, S | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Vyas, S | 1 |
| Roberti, I | 1 |
| McCarthy, C | 1 |
| Zauner, C | 1 |
| Funk, GC | 1 |
| Birnbacher, R | 1 |
| Zoja, C | 3 |
| Perico, N | 3 |
| Remuzzi, G | 3 |
| Bertani, T | 2 |
| Bergamelli, A | 1 |
| Pasini, M | 1 |
| Morigi, M | 1 |
| Dadan, J | 1 |
| Belloni, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
5 reviews available for ticlopidine and Kidney Diseases
| Article | Year |
|---|---|
Proton pump inhibitors: Risks of long-term use.
Topics: Calcium; Cardiovascular Diseases; Clopidogrel; Dementia; Drug Interactions; Fractures, Bone; Gastroi | 2017 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Review of antithrombotic agents used for acute coronary syndromes in renal patients.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Fib | 2003 |
Antiplatelet agents: effects on the progressive renal disease.
Topics: Animals; Anticoagulants; Blood Platelets; Humans; Kidney; Kidney Diseases; Platelet Aggregation Inhi | 1991 |
4 trials available for ticlopidine and Kidney Diseases
| Article | Year |
|---|---|
Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aprotinin; Blood Transfusion; Cerebrovascular Disorders; Clopidogrel | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney di
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cilostazol; Clopidogrel; Coronary Arte | 2011 |
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb | 2012 |
20 other studies available for ticlopidine and Kidney Diseases
| Article | Year |
|---|---|
Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Blood Urea Nitrogen; Clopidogrel; Creatinine; Drug The | 2016 |
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity.
Topics: Aged; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Female; Humans; Kidney Diseases; Male; | 2013 |
Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel.
Topics: Acute Disease; Age Factors; Aged; Anticoagulants; Chronic Disease; Clopidogrel; Female; Gastrointest | 2014 |
Spontaneous renal parenchymal hematoma associated with clopidogrel in a patient with diabetic nephropathy.
Topics: Aged; Clopidogrel; Diabetic Nephropathies; Hematoma; Humans; Kidney Diseases; Male; Platelet Aggrega | 2015 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.
Topics: Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Asian People; Biomarkers; B | 2012 |
[Risk factors and subjective symptoms of drug-induced leucopenia].
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Autoimmune Dise | 2011 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction?
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Clopidogrel; Drug Interactions; Dyspnea; Glomeru | 2012 |
Serious clopidogrel associated renal hematoma in a type 2 diabetic patient with primary hyperparathyroidism after extracorporeal shock wave lithotripsy.
Topics: Clopidogrel; Diabetes Mellitus, Type 2; Hematoma; Humans; Hyperparathyroidism, Primary; Kidney Calcu | 2005 |
Ticlopidine-induced lupus with renal involvement.
Topics: Aged; Fibrinolytic Agents; Glomerulonephritis; Humans; Kidney; Kidney Diseases; Lupus Erythematosus, | 2006 |
Spontaneous abdominal hematoma in a patient treated with clopidogrel and aspirin.
Topics: Abdominal Cavity; Abdominal Pain; Aged; Aspirin; Clopidogrel; Hematoma; Humans; Kidney Diseases; Mal | 2006 |
Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure.
Topics: Aged; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Creatinine; Female | 2007 |
Management of a spontaneous renal capsule hematoma following cardiac catheterization involving use of a platelet glycoprotein IIb/IIIa inhibitor: a case report.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Catheterization; Clopidogrel; Cor | 2007 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood | 2008 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
May-Thurner syndrome in a pediatric renal transplant recipient--case report and literature review.
Topics: Adolescent; Clopidogrel; Creatinine; Edema; Female; Graft Survival; Humans; Iliac Vein; Kidney Disea | 2008 |
Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
Topics: Acute Disease; Critical Care; Drug Eruptions; Drug Monitoring; Gastrointestinal Diseases; Humans; Ki | 2001 |
Effect of ticlopidine on the evolution of renal disease in rats with reduced renal mass.
Topics: Adenosine Diphosphate; Animals; Bleeding Time; Kidney; Kidney Diseases; Male; Organ Size; Platelet A | 1990 |
Ticlopidine prevents renal disease progression in rats with reduced renal mass.
Topics: Animals; Biphenyl Compounds; Bleeding Time; Blood Pressure; Hematocrit; Heptanoic Acids; Infarction; | 1990 |